References
- Ahn SY, Chang YS, Kim JH, et al. (2017). Two-year follow-up outcomes of premature infants enrolled in the Phase I trial of mesenchymal stem cells transplantation for bronchopulmonary dysplasia. J Pediatr 185:49–54.e2.
- Barile L, Vassalli G. (2017). Exosomes: therapy delivery tools and biomarkers of diseases. Pharmacol Ther 174:63–78.
- Batrakova EV, Kim MS. (2015). Using exosomes, naturally-equipped nanocarriers, for drug delivery. J Control Release 219:396–405.
- Biban P, Chini L, Bonetti P, et al. (2012). Exogenous surfactant replacement: how to deliver it? Acta Biomed 83:27–32.
- Bunggulawa EJ, Wang W, Yin T, et al. (2018). Recent advancements in the use of exosomes as drug delivery systems. J Nanobiotechnology 16:81.
- Chang YS, Ahn SY, Yoo HS, et al. (2014). Mesenchymal stem cells for bronchopulmonary dysplasia: phase 1 dose-escalation clinical trial. J Pediatr 164:966–72.e6.
- Chen CM, Chang CH, Chao CH, et al. (2019). Biophysical and chemical stability of surfactant/budesonide and the pulmonary distribution following intra-tracheal administration. Drug Deliv 26:604–11.
- Collins A. (2020). Stem-cell therapy for bronchopulmonary dysplasia. Curr Opin Pediatr 32:210–5.
- De Jong WH, Borm PJ. (2008). Drug delivery and nanoparticles:applications and hazards. Int J Nanomedicine 3:133–49.
- Engür D, Kumral A. (2012). Surfactant protein D as a novel therapy for periventricular leukomalacia: is it the missing piece of the puzzle? ACS Chem Neurosci 3:990.
- Herting E, Gefeller O, Land M, et al. (2000). Surfactant treatment of neonates with respiratory failure and group B streptococcal infection. Members of the Collaborative European Multicenter Study Group. Pediatrics 106:957–64.
- Jacot W, Bousquet J. (2003). Understanding the regulation of surfactant gene expression. Eur Respir J 22:6–7.
- Kalluri R, LeBleu VS. (2020). The biology, function, and biomedical applications of exosomes. Science 367:aau6977.
- Lesage F, Thébaud B. (2018). Nanotherapies for micropreemies: stem cells and the secretome in bronchopulmonary dysplasia. Semin Perinatol 42:453–8.
- Lin J, Li J, Huang B, et al. (2015). Exosomes: novel biomarkers for clinical diagnosis. Sci World J 2015:657086.
- Luan X, Sansanaphongpricha K, Myers I, et al. (2017). Engineering exosomes as refined biological nanoplatforms for drug delivery. Acta Pharmacol Sin 38:754–63.
- Niemarkt HJ, Hütten MC, Kramer BW. (2017). Surfactant for respiratory distress syndrome: new ideas on a familiar drug with innovative applications. Neonatology 111:408–14.
- Pegtel DM, Gould SJ. (2019). Exosomes. Annu Rev Biochem 88:487–514.
- Salgado D, Fischer R, Schillberg S, et al. (2014). Comparative evaluation of heterologous production systems for recombinant pulmonary surfactant protein D. Front Immunol 5:623.
- Turchinovich A, Drapkina O, Tonevitsky A. (2019). Transcriptome of extracellular vesicles: state- of-the-art. Front Immunol 10:202.
- Willis GR, Fernandez-Gonzalez A, Anastas J, et al. (2018). Mesenchymal stromal cell exosomes ameliorate experimental bronchopulmonary dysplasia and restore lung function through macrophage immunomodulation. Am J Respir Crit Care Med 197:104–16.